Pharmaceuticals News and Research

RSS

Cooperation needed to fight NCDs, U.N. officials note

Speaking Thursday at an informal civil society hearing that is a precursor to the first-ever high-level meeting on non-communicable diseases (NCDs), top U.N. officials "stressed the need for governments, the private sector and civil society to work together and more effectively to address cancers, diabetes and other non-communicable diseases, which account for nearly two thirds of global deaths each year," the U.N. News Centre reports.

18 Jun 2011

RHEI receives Chinese SFDA acceptance letter for MuGard

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that its MuGard partner in China, RHEI Pharmaceuticals has received the acceptance letter from the State Food and Drug Administration (SFDA) of China acknowledging all necessary documentation for the MuGard has been submitted and accepted.

17 Jun 2011

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Jewish General Hospital, one of McGill University's Hospital Centers, to conduct the necessary research and development to advance Sunshine's lead compound, Adva-27a, through the various stages of preclinical studies and Phase I clinical trials.

17 Jun 2011

NASDAQ halts Regeneron's common stock

Regeneron Pharmaceuticals, Inc. announced that NASDAQ has halted trading of the company's common stock.

17 Jun 2011

Women, young people more worried about EHEC bacteria outbreak in Europe

The news coverage of the deadly EHEC bacteria outbreak in Europe came as a bombshell. Ghent University (Belgium) examined 6132 reactions of Belgian newspaper readers after reading the first news reports.

17 Jun 2011

Joint venture to manufacture and distribute tenofovir gel in Africa

CONRAD and the South African Government's Technology Innovation Agency (TIA) on Tuesday announced a license agreement that grants TIA the rights to manufacture and distribute tenofovir gel in Africa, according to a CONRAD statement.

17 Jun 2011

Roche RTCA HT Instrument allows fully-automated impedance screens for GPCRs

Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.

17 Jun 2011

$New report: Only minority of high risk patients receive treatment to prevent fractures$

New report: Only minority of high risk patients receive treatment to prevent fractures

In Europe, a serious treatment gap is leaving millions of people at high risk of fragility fractures. The findings were revealed in 'Osteoporosis: Burden, health care provision and opportunities in the EU', a landmark report prepared by the International Osteoporosis Foundation (IOF) in collaboration with the European Federation of Pharmaceutical Industry Associations.

17 Jun 2011

More money needed to fight health issues

"I can't help worrying that, as donors slap themselves on the back over their generosity [shown through pledges to the GAVI Alliance] …, their feelgood factor will turn into a warm glow of satisfaction at having played out their part. Problem solved," Sarah Boseley writes on the Guardian's "Global Health Blog."

17 Jun 2011

Scientists uncover how immune system responds to invading anthrax bacteria

Scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have uncovered how the body's immune system launches its survival response to the notorious and deadly bacterium anthrax.

17 Jun 2011

BioClinica releases new Trident IWR solution

BioClinica, Inc., a global provider of clinical trial management solutions, today announced a new release of Trident IWR, the latest addition to its best-in-class suite of eClinical applications.

From Clario 17 Jun 2011

New Australian drug shows positive response in patients with multiple myeloma blood cancer

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer.

16 Jun 2011

CEVEC and Catalent Pharma Solutions offer joint cell line development service

CEVEC Pharmaceuticals, the German developer of a novel, market leading human protein expression system derived from amniocytes, and Catalent Pharma Solutions, a leading global drug development and delivery solutions provider, announced today a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVEC’s human cell line, CAP-Technology, with Catalent’s unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.

16 Jun 2011

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Aradigm Corporation today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORBIT-1) with Aradigm's ciprofloxacin for inhalation (CFI, ARD-3100, LipoquinTM) in patients with non-cystic fibrosis bronchiectasis (BE).

16 Jun 2011

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

16 Jun 2011

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

European scientists develop efficient methods for early diagnosis of Alzheimer's

PredictAD is an EU-funded research project that develops objective and efficient methods for enabling earlier diagnosis of Alzheimer's disease. Diagnosis requires a holistic view of the patient combining information from several sources, such as, clinical tests, imaging and blood samples.

16 Jun 2011

Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza

BiondVax Pharmaceuticals Ltd. today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.

16 Jun 2011

$Economic burden of fractures in Europe has been vastly underestimated: New report$

Economic burden of fractures in Europe has been vastly underestimated: New report

A new report launched today by the International Osteoporosis Foundation (IOF) in collaboration with the European Federation of Pharmaceutical Industry Associations (EFPIA) reveals that the burden of fractures in Europe has been vastly underestimated.

16 Jun 2011

ClinTec opens fully registered offices in China, Singapore and Thailand for clinical research

UK based Global Clinical Research Organisation (CRO), ClinTec International has continued its international expansion by opening fully registered offices in China, Singapore and Thailand - consolidating its presence in the Asia Pacific region.

16 Jun 2011

Pharmaceuticals News and Research

Cooperation needed to fight NCDs, U.N. officials note

RHEI receives Chinese SFDA acceptance letter for MuGard

Sunshine enters Adva-27a cancer research and development agreement with The Jewish General Hospital

NASDAQ halts Regeneron's common stock

Women, young people more worried about EHEC bacteria outbreak in Europe

Joint venture to manufacture and distribute tenofovir gel in Africa

Roche RTCA HT Instrument allows fully-automated impedance screens for GPCRs

New report: Only minority of high risk patients receive treatment to prevent fractures

More money needed to fight health issues

Scientists uncover how immune system responds to invading anthrax bacteria

BioClinica releases new Trident IWR solution

New Australian drug shows positive response in patients with multiple myeloma blood cancer

CEVEC and Catalent Pharma Solutions offer joint cell line development service

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

European scientists develop efficient methods for early diagnosis of Alzheimer's

Positive results from BiondVax Multimeric-001 Phase IIa trial against influenza

Economic burden of fractures in Europe has been vastly underestimated: New report

ClinTec opens fully registered offices in China, Singapore and Thailand for clinical research

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence